Claudin 4 Is Differentially Expressed between Ovarian Cancer Subtypes and Plays a Role in Spheroid Formation

被引:31
|
作者
Boylan, Kristin L. M. [1 ]
Misemer, Benjamin [1 ]
DeRycke, Melissa S. [1 ]
Andersen, John D. [1 ]
Harrington, Katherine M. [1 ]
Kalloger, Steve E. [2 ]
Gilks, C. Blake [2 ]
Pambuccian, Stefan E. [1 ]
Skubitz, Amy P. N. [1 ]
机构
[1] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
[2] British Columbia Canc Agcy, Cheryl Brown Ovarian Canc Outcomes Unit, Vancouver, BC V5Z 4E6, Canada
基金
美国国家卫生研究院;
关键词
ovarian cancer; claudin; 4; biomarker; spheroid; ascites; JUNCTION-ASSOCIATED PROTEINS; SQUAMOUS-CELL CARCINOMA; C-TERMINAL FRAGMENT; GENE-EXPRESSION; REDUCED EXPRESSION; DOWN-REGULATION; DECREASED EXPRESSION; BREAST CARCINOMAS; RECURRENCE STATUS; BARRIER FUNCTION;
D O I
10.3390/ijms12021334
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Claudin 4 is a cellular adhesion molecule that is frequently overexpressed in ovarian cancer and other epithelial cancers. In this study, we sought to determine whether the expression of claudin 4 is associated with outcome in ovarian cancer patients and may be involved in tumor progression. We examined claudin 4 expression in ovarian cancer tissues and cell lines, as well as by immunohistochemical staining of tissue microarrays (TMAs; n = 500), spheroids present in patients' ascites, and spheroids formed in vitro. Claudin 4 was expressed in nearly 70% of the ovarian cancer tissues examined and was differentially expressed across ovarian cancer subtypes, with the lowest expression in clear cell subtype. No association was found between claudin 4 expression and disease-specific survival in any subtype. Claudin 4 expression was also observed in multicellular spheroids obtained from patients' ascites. Using an in vitro spheroid formation assay, we found that NIH:OVCAR5 cells treated with shRNA against claudin 4 required a longer time to form compact spheroids compared to control NIH:OVCAR5 cells that expressed high levels of claudin 4. The inability of the NIH:OVCAR5 cells treated with claudin 4 shRNA to form compact spheroids was verified by FITC-dextran exclusion. These results demonstrate a role for claudin 4 and tight junctions in spheroid formation and integrity.
引用
收藏
页码:1334 / 1358
页数:25
相关论文
共 50 条
  • [21] Identification of differentially expressed genes and signaling pathways in ovarian cancer by integrated bioinformatics analysis
    Yang, Xiao
    Zhu, Shaoming
    Li, Li
    Zhang, Li
    Xian, Shu
    Wang, Yanqing
    Cheng, Yanxiang
    ONCOTARGETS AND THERAPY, 2018, 11 : 1457 - 1474
  • [22] Phosphorylation of claudin-4 by PKCε regulates tight junction barrier function in ovarian cancer cells
    D'Souza, Theresa
    Indig, Fred E.
    Morin, Patrice J.
    EXPERIMENTAL CELL RESEARCH, 2007, 313 (15) : 3364 - 3375
  • [23] Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response
    de la Fuente, Laura Martin
    Malander, Susanne
    Hartman, Linda
    Jonsson, Jenny-Maria
    Ebbesson, Anna
    Nilbert, Mef
    Masback, Anna
    Hedenfalk, Ingrid
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2018, 37 (02) : 101 - 109
  • [24] Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility
    Lu, Renquan
    Sun, Xinghui
    Xiao, Ran
    Zhou, Lei
    Gao, Xiang
    Guo, Lin
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2012, 419 (02) : 274 - 280
  • [25] α-SNAP is expressed in mouse ovarian granulosa cells and plays a key role in folliculogenesis and female fertility
    Arcos, Alexis
    de Paola, Matilde
    Gianetti, Diego
    Acuna, Diego
    Velasquez, Zahady D.
    Paz Miro, Maria
    Toro, Gabriela
    Hinrichsen, Bryan
    Iris Munoz, Rosa
    Lin, Yimo
    Mardones, Gonzalo A.
    Ehrenfeld, Pamela
    Rivera, Francisco J.
    Michaut, Marcela A.
    Federico Batiz, Luis
    SCIENTIFIC REPORTS, 2017, 7
  • [26] Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes
    Kommoss, Stefan
    Winterhoff, Boris
    Oberg, Ann L.
    Konecny, Gottfried E.
    Wang, Chen
    Riska, Shaun M.
    Fan, Jian-Bing
    Maurer, Matthew J.
    April, Craig
    Shridhar, Viji
    Kommoss, Friedrich
    du Bois, Andreas
    Hilpert, Felix
    Mahner, Sven
    Baumann, Klaus
    Schroeder, Willibald
    Burges, Alexander
    Canzler, Ulrich
    Chien, Jeremy
    Embleton, Andrew C.
    Parmar, Mahesh
    Kaplan, Richard
    Perren, Timothy
    Hartmann, Lynn C.
    Goode, Ellen L.
    Dowdy, Sean C.
    Pfisterer, Jacobus
    CLINICAL CANCER RESEARCH, 2017, 23 (14) : 3794 - 3801
  • [27] Ovarian Cancer: Differentially Expressed microRNAs in Tumor Tissue and Cell-Free Ascitic Fluid as Potential Novel Biomarkers
    Zavesky, Ludek
    Jandakova, Eva
    Weinberger, Vit
    Minar, Lubos
    Hanzikova, Veronika
    Duskova, Daniela
    Zaveska Drabkova, Lenka
    Horinek, Ales
    CANCER INVESTIGATION, 2019, 37 (09) : 440 - 452
  • [28] Beyond tumor-associated macrophages involved in spheroid formation and dissemination: Novel insights for ovarian cancer therapy (Review)
    Liu, Yuchen
    Xiao, Haoyue
    Zeng, Hai
    Xiang, Ying
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2024, 65 (06)
  • [29] Angiotensin II promotes ovarian cancer spheroid formation and metastasis by upregulation of lipid desaturation and suppression of endoplasmic reticulum stress
    Zhang, Qingyu
    Yu, Shan
    Lam, Melody Man Ting
    Poon, Terence Chuen Wai
    Sun, Litao
    Jiao, Yufei
    Wong, Alice Sze Tsai
    Lee, Leo Tsz On
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
  • [30] The metabolic cross-talk between epithelial cancer cells and stromal fibroblasts in ovarian cancer progression: Autophagy plays a role
    Thuwajit, Chanitra
    Ferraresi, Alessandra
    Titone, Rossella
    Thuwajit, Peti
    Isidoro, Ciro
    MEDICINAL RESEARCH REVIEWS, 2018, 38 (04) : 1235 - 1254